MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt
· Delayed Price · Currency is EGP 234.45
-9.03 (-3.71%)
At close: Jun 12, 2025
MINAPHARM Pharmaceuticals Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 5,665 | 3,892 | 3,621 | 3,005 | 2,361 | Upgrade
|
Revenue Growth (YoY) | 45.55% | 7.50% | 20.47% | 27.29% | 15.11% | Upgrade
|
Cost of Revenue | 3,728 | 2,640 | 2,124 | 1,820 | 1,457 | Upgrade
|
Gross Profit | 1,937 | 1,252 | 1,496 | 1,185 | 904.48 | Upgrade
|
Selling, General & Admin | 828.91 | 718.51 | 474.95 | 392.79 | 326.6 | Upgrade
|
Research & Development | 131.26 | 151.27 | 59.35 | 45.84 | 39.08 | Upgrade
|
Operating Expenses | 1,003 | 876.91 | 531.63 | 431.37 | 365.68 | Upgrade
|
Operating Income | 933.85 | 374.66 | 964.74 | 753.96 | 538.8 | Upgrade
|
Interest Expense | -593.68 | -254.46 | -62.17 | -48.84 | -69.3 | Upgrade
|
Interest & Investment Income | 46.56 | 14.06 | 9.55 | 5.08 | 5.8 | Upgrade
|
Currency Exchange Gain (Loss) | 10.67 | -37.3 | 37.52 | -1.76 | 1.64 | Upgrade
|
Other Non Operating Income (Expenses) | -117.27 | -63.76 | -69.3 | -40.66 | -45 | Upgrade
|
EBT Excluding Unusual Items | 280.12 | 33.2 | 880.34 | 667.79 | 431.95 | Upgrade
|
Gain (Loss) on Sale of Assets | -0.45 | -0.17 | - | 0.46 | - | Upgrade
|
Pretax Income | 279.67 | 33.03 | 880.34 | 668.25 | 431.95 | Upgrade
|
Income Tax Expense | 118.57 | 10.67 | 249.44 | 193.38 | 121.27 | Upgrade
|
Earnings From Continuing Operations | 161.11 | 22.36 | 630.89 | 474.87 | 310.68 | Upgrade
|
Minority Interest in Earnings | -4.04 | -54.35 | -18.23 | -8.46 | -9.9 | Upgrade
|
Net Income | 157.07 | -31.99 | 612.66 | 466.41 | 300.78 | Upgrade
|
Preferred Dividends & Other Adjustments | 28.91 | 23.4 | 22.75 | 18.7 | 15.53 | Upgrade
|
Net Income to Common | 128.15 | -55.39 | 589.91 | 447.71 | 285.25 | Upgrade
|
Net Income Growth | - | - | 31.36% | 55.06% | 113.18% | Upgrade
|
Shares Outstanding (Basic) | 11 | 11 | 11 | 12 | 12 | Upgrade
|
Shares Outstanding (Diluted) | 11 | 11 | 11 | 12 | 12 | Upgrade
|
Shares Change (YoY) | - | -3.57% | -6.67% | - | - | Upgrade
|
EPS (Basic) | 11.58 | -5.01 | 51.41 | 36.42 | 23.20 | Upgrade
|
EPS (Diluted) | 11.58 | -5.01 | 51.41 | 36.42 | 23.20 | Upgrade
|
EPS Growth | - | - | 41.17% | 56.95% | 102.17% | Upgrade
|
Free Cash Flow | -697.45 | -1,292 | -598.45 | -180.6 | 286.84 | Upgrade
|
Free Cash Flow Per Share | -63.04 | -116.81 | -52.16 | -14.69 | 23.33 | Upgrade
|
Dividend Per Share | - | 1.650 | 2.800 | 2.922 | 2.700 | Upgrade
|
Dividend Growth | - | -41.07% | -4.17% | 8.21% | - | Upgrade
|
Gross Margin | 34.19% | 32.16% | 41.33% | 39.44% | 38.31% | Upgrade
|
Operating Margin | 16.48% | 9.63% | 26.65% | 25.09% | 22.82% | Upgrade
|
Profit Margin | 2.26% | -1.42% | 16.29% | 14.90% | 12.08% | Upgrade
|
Free Cash Flow Margin | -12.31% | -33.21% | -16.53% | -6.01% | 12.15% | Upgrade
|
EBITDA | 1,172 | 536.04 | 1,086 | 835.91 | 621.7 | Upgrade
|
EBITDA Margin | 20.69% | 13.77% | 29.99% | 27.81% | 26.33% | Upgrade
|
D&A For EBITDA | 238.38 | 161.38 | 121.14 | 81.95 | 82.9 | Upgrade
|
EBIT | 933.85 | 374.66 | 964.74 | 753.96 | 538.8 | Upgrade
|
EBIT Margin | 16.48% | 9.63% | 26.65% | 25.09% | 22.82% | Upgrade
|
Effective Tax Rate | 42.39% | 32.29% | 28.34% | 28.94% | 28.07% | Upgrade
|
Advertising Expenses | - | - | 8.4 | 15.38 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.